報價延遲最少15分鐘:2025/06/02 07:29 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
56.02 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
3.76/7.25
|
|
企業價值
8.25B
|
| 資產負債 |
|
每股賬面淨值
3.91
|
| 現金流量 |
|
現金流量率
0.07
|
| 損益表 |
|
收益
1.02B
|
|
每股收益
6.34
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/02 07:29 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |